List of Excipients in Branded Drug SUDAFED SINUS CONGESTION 24 HOUR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Johnson & Johnson Consumer Inc	SUDAFED SINUS CONGESTION 24 HOUR	pseudoephedrine hydrochloride	50580-240	CELLULOSE, MICROCRYSTALLINE
Johnson & Johnson Consumer Inc	SUDAFED SINUS CONGESTION 24 HOUR	pseudoephedrine hydrochloride	50580-240	FERROSOFERRIC OXIDE
Johnson & Johnson Consumer Inc	SUDAFED SINUS CONGESTION 24 HOUR	pseudoephedrine hydrochloride	50580-240	HYDROXYPROPYL CELLULOSE
Johnson & Johnson Consumer Inc	SUDAFED SINUS CONGESTION 24 HOUR	pseudoephedrine hydrochloride	50580-240	HYPROMELLOSE

Excipient Strategy and Commercial Opportunities for Sudafed Sinus Congestion 24 Hour

Last updated: August 26, 2026

Sudafed Sinus Congestion 24 Hour is an extended-release oral pseudoephedrine hydrochloride product. Its commercial value is driven by once-daily dosing, brand recognition, and access to a legally established OTC decongestant category rather than by a complex active pharmaceutical ingredient patent estate. The strongest excipient opportunities are improved release control, tablet robustness, abuse-deterrence support, swallowability, and manufacturing efficiency.

The product’s active ingredient is pseudoephedrine hydrochloride, 240 mg per extended-release tablet. The labeled adult dose is one tablet every 24 hours, with a maximum of one tablet in 24 hours.[1] Pseudoephedrine products remain subject to federal retail controls because of diversion concerns, including purchase limits, sales records, identification requirements, and behind-the-counter handling.[2]

What is Sudafed Sinus Congestion 24 Hour?

Sudafed Sinus Congestion 24 Hour is an oral extended-release decongestant indicated for temporary relief of nasal and sinus congestion and sinus pressure.[1]

Attribute	Product position
Brand	Sudafed
Product	Sinus Congestion 24 Hour
Active ingredient	Pseudoephedrine hydrochloride
Strength	240 mg extended-release tablet
Route	Oral
Dosing	One tablet every 24 hours for adults and children 12 years and older
Therapeutic class	Systemic nasal decongestant
Regulatory route	OTC drug product
Primary formulation challenge	Maintaining 24-hour release of a highly water-soluble active
Key commercial constraint	Federal and state pseudoephedrine sales controls

The product is distinct from Sudafed PE products, which contain phenylephrine. Pseudoephedrine and phenylephrine have different active ingredients, regulatory histories, pharmacokinetic profiles, and formulation requirements.

What excipients are strategically important in a 24-hour pseudoephedrine tablet?

The excipient system must control pseudoephedrine release over approximately one day while maintaining tablet integrity, acceptable swallowing characteristics, chemical stability, and consistent dissolution.

A typical formulation architecture for this product category may include the following functional excipient groups:

Excipient function	Commercial purpose	Main technical risk
Hydrophilic matrix former	Slows water penetration and drug diffusion	Dose dumping if polymer level or grade is poorly controlled
Hydrophobic release modifier	Extends release and reduces burst effect	Variable dissolution and poor tablet wettability
Binder	Provides mechanical strength during compression	Excessive hardness can delay release
Diluent	Controls tablet size, density, and manufacturability	Large tablet burden at a 240 mg dose
Disintegrant	Supports controlled erosion or residual breakup	Excessive disintegration can compromise extended release
Lubricant	Prevents sticking and improves ejection	Over-lubrication can reduce dissolution
Glidant	Improves powder flow	Segregation risk in high-dose blends
Film coat	Improves appearance, handling, and swallowability	Coating defects or altered water ingress
Opacifier or colorant	Supports product identification and brand differentiation	Regulatory and consumer-perception constraints

The commercial formulation objective is not simply to slow dissolution. It is to create a reproducible release profile that remains stable across manufacturing lots, storage conditions, gastrointestinal pH, and normal variability in tablet handling.

How does the active ingredient affect excipient selection?

Pseudoephedrine hydrochloride is a highly water-soluble salt. That characteristic creates a release-control problem because a conventional immediate-release matrix can permit rapid water penetration and drug diffusion.

The excipient strategy therefore should prioritize:

1. A high-viscosity hydrophilic polymer or polymer combination.
2. Sufficient matrix integrity after hydration.
3. Controlled tablet porosity.
4. Low sensitivity to compression-force variation.
5. Robust dissolution performance across pH conditions.
6. Protection against mechanical damage during packaging and distribution.

Hydrophilic matrices based on hypromellose are commercially established for extended-release products. Grades with different viscosity and particle-size characteristics can materially change gel strength, hydration rate, and drug release. Polymer selection can therefore create formulation differentiation without changing the active ingredient.

Hydrophobic excipients, including waxy or lipid-based release modifiers, may support longer release but can introduce greater batch-to-batch variability. They also may complicate scale-up and dissolution method development. A mixed hydrophilic-hydrophobic system can improve release control, but it increases formulation and regulatory complexity.

What formulation patents could protect a Sudafed 24-hour product?

Protection would most likely focus on formulation performance rather than pseudoephedrine itself. Relevant claim categories include:

• Extended-release tablets containing pseudoephedrine hydrochloride and specified polymer ranges.
• Dissolution profiles measured at defined time points.
• Multilayer or coated matrix tablets.
• Abuse-deterrent formulations that resist crushing, extraction, or rapid release.
• Tablet compositions with reduced size or improved swallowability.
• Manufacturing processes that produce consistent release across compression-force ranges.
• Packaging systems that limit moisture uptake or tampering.
• Combination products containing pseudoephedrine and another active ingredient.

A formulation patent is strongest when it links composition to a measurable technical result. Broad claims covering pseudoephedrine plus a conventional matrix polymer may face validity and obviousness challenges. Narrow claims tied to a distinctive dissolution profile, manufacturing process, or abuse-deterrence mechanism may be more defensible but provide narrower commercial coverage.

What is the Orange Book status of Sudafed Sinus Congestion 24 Hour?

Sudafed Sinus Congestion 24 Hour is an OTC product marketed in a monograph-based regulatory environment rather than a conventional prescription NDA framework. The FDA OTC monograph system establishes conditions for marketing certain nonprescription drugs without an individual product approval application.[3]

As a result:

• The product should not be analyzed as if it had a conventional Orange Book-listed NDA patent estate.
• Orange Book-listed patents and Paragraph IV litigation are generally not the principal exclusivity mechanism.
• Competitive protection is more likely to arise from trademarks, formulation know-how, manufacturing scale, retailer relationships, packaging, and any separately developed patent rights.
• A private-label or generic-style competitor may enter if it satisfies the applicable OTC regulatory conditions and complies with pseudoephedrine controls.

When does Sudafed Sinus Congestion 24 Hour lose exclusivity?

The product does not have a conventional patent-cliff analysis comparable to a patented prescription drug. Its commercial exclusivity is already exposed to OTC competition, subject to branding, formulation differences, regulatory compliance, and distribution controls.

The relevant exclusivity layers are:

Exclusivity layer	Relevance
Active-ingredient exclusivity	Limited because pseudoephedrine is an established OTC active
NDA exclusivity	Not the primary framework for a monograph OTC product
Orange Book patent listing	Generally not the central competitive mechanism
Formulation patents	Potentially relevant if valid and enforceable
Trademark protection	Important for the Sudafed brand
Trade secrets	Important for release-control and manufacturing parameters
Retail execution	Important because pseudoephedrine sales controls affect availability
Packaging and product presentation	Supports differentiation but usually provides limited legal exclusivity

A competitor does not necessarily need to copy the exact Sudafed formulation. It can commercialize a compliant 24-hour pseudoephedrine product using a different excipient system, provided the product meets applicable FDA requirements and labeling standards.

What generic entry risks exist for Sudafed Sinus Congestion 24 Hour?

Generic and private-label entry risk is structurally high because the active ingredient is mature and the product category is established. The principal barriers are operational rather than molecule-specific.

Regulatory barriers

Competitors must comply with FDA OTC requirements, including active-ingredient conditions, dosage, labeling, warnings, and product quality standards.[3] A 24-hour extended-release product also requires suitable performance data demonstrating that the formulation behaves as labeled.

Manufacturing barriers

The key manufacturing challenges are:

• Uniform distribution of a high-dose active ingredient.
• Control of tablet hardness and porosity.
• Reproducible polymer hydration.
• Prevention of capping, sticking, and lamination.
• Consistent dissolution after scale-up.
• Moisture control during compression and packaging.
• Robustness through high-volume packaging lines.

Commercial barriers

Pseudoephedrine purchase restrictions complicate retail execution. Federal law limits the amount an individual may purchase and requires sellers to maintain transaction records.[2] State-level requirements can be more restrictive. These controls increase compliance costs and can affect inventory turnover, online fulfillment, and retailer willingness to stock competing products.

Product-performance barriers

A competitor must match the consumer proposition: one tablet, once daily, with reliable congestion relief. A product that releases too rapidly may fail the extended-release positioning. A product that releases too slowly may produce delayed onset or inadequate relief.

How can excipients create commercial opportunities?

Reduced tablet size

Pseudoephedrine hydrochloride accounts for a substantial portion of the tablet mass. A higher-efficiency matrix system could reduce total tablet weight while maintaining the same active dose and release profile.

Commercial benefits include:

• Improved swallowing.
• Lower packaging volume.
• Lower shipping and storage cost.
• Better consumer acceptance.
• Potential differentiation from large conventional extended-release tablets.

The technical limitation is that reducing excipient mass can reduce matrix integrity and narrow the manufacturing operating window.

Improved abuse deterrence

Pseudoephedrine is subject to diversion because it can be used as a precursor in illicit methamphetamine production. A formulation that is difficult to crush, extract, or rapidly dissolve could reduce misuse potential and support retailer acceptance.

Potential approaches include:

• Tough polymer matrices.
• Gel-forming systems.
• Crush-resistant tablet structures.
• Coatings that limit solvent penetration.
• Combination systems that create unpleasant physical properties upon tampering.

The legal and commercial value of abuse deterrence depends on demonstrated performance. A simple hard tablet is unlikely to support strong claims unless it resists relevant manipulation methods.

Lower-cost manufacturing

Excipient optimization can reduce cost by improving:

• Direct-compression suitability.
• Powder flow.
• Tablet yield.
• Compression speed.
• Coating efficiency.
• Product stability.
• Packaging compatibility.

A formulation with fewer excipients may reduce procurement complexity, but simplification can increase reliance on a single polymer or narrow the process window. The lowest unit cost does not necessarily produce the lowest total cost if batch failures or dissolution deviations increase.

Improved stability

Moisture-sensitive release matrices can change dissolution during storage. Excipient and packaging strategies may include:

• Low-moisture excipient grades.
• Desiccant-containing bottles.
• High-barrier blister packaging.
• Moisture-resistant film coatings.
• Tighter control of residual solvents and water activity.

Stability improvement can reduce out-of-specification risk and support distribution into humid markets.

Pediatric and geriatric usability

The labeled product is intended for adults and children 12 years and older. A commercial opportunity exists for a more swallowable tablet or an alternative dosage form, but a liquid or chewable pseudoephedrine product would create difficult release-control and misuse-management issues.

Multiparticulate capsules, mini-tablets, or coated pellets could improve administration flexibility. These formats would require careful control of dose uniformity, accidental chewing, and release behavior.

Which competing products matter?

The most relevant competitive set includes:

Product type	Active ingredient	Release profile	Competitive implication
Sudafed Sinus Congestion 24 Hour	Pseudoephedrine hydrochloride	Extended release	Brand benchmark for once-daily systemic decongestion
Generic pseudoephedrine ER	Pseudoephedrine hydrochloride	Extended release	Direct price and formulation competitor
Immediate-release pseudoephedrine	Pseudoephedrine hydrochloride	Immediate release	Lower unit price but more frequent dosing
Sudafed PE products	Phenylephrine hydrochloride	Usually immediate release	Same brand family but different active ingredient
Combination cold products	Pseudoephedrine plus other actives	Immediate or extended release	Broader symptom coverage and higher formulation complexity

Phenylephrine products should not be treated as direct substitutes in patent or formulation analysis. They use a different active ingredient and have different efficacy and regulatory considerations. The FDA has stated that oral phenylephrine is not effective as a nasal decongestant at the recommended OTC dose, while pseudoephedrine remains a distinct active ingredient with a different evidence base.[4]

Which companies are challenging the Sudafed commercial position?

The principal competitive threat comes from generic and store-brand manufacturers rather than from biosimilar developers or traditional Paragraph IV challengers. Likely competitor categories include large generic manufacturers, contract manufacturers, pharmacy chains, mass retailers, and private-label consumer-health companies.

Competition can occur through:

• Store-brand pseudoephedrine extended-release tablets.
• Lower-priced immediate-release products.
• Alternative branded decongestants.
• Combination products.
• E-commerce and pharmacy-channel substitution.

A direct formulation copy is not necessary. A competitor can use a different matrix polymer, compression process, coating system, or packaging format.

What patent litigation and Paragraph IV risks affect the product?

No conventional Paragraph IV litigation strategy is central to a monograph OTC product. Paragraph IV certification applies to abbreviated new drug applications referencing an NDA and challenging listed patents. A monograph-based pseudoephedrine product generally does not create the same ANDA patent-certification pathway.[3]

Litigation risk may still arise from:

• Formulation patents.
• Trade dress and trademark disputes.
• False advertising claims involving 24-hour relief or abuse deterrence.
• Manufacturing-process patents.
• Packaging patents.
• Contract-manufacturing disputes.
• Product-liability claims involving misuse or dosing errors.

The strongest litigation position would likely require a specific, enforceable formulation or process patent. Brand recognition alone does not block lawful OTC competition.

What licensing opportunities exist for excipient technology?

The most attractive licensing opportunities are platform technologies that can be applied across multiple extended-release products.

Potential licensing targets include:

1. High-solubility drug matrix systems.
2. Abuse-deterrent oral dosage forms.
3. Low-mass, high-strength tablet technologies.
4. Moisture-resistant coating systems.
5. Multiparticulate extended-release platforms.
6. Continuous manufacturing processes for matrix tablets.
7. Dissolution-control technologies that reduce sensitivity to compression force.

A licensee would likely prioritize technologies with data in highly water-soluble actives, because pseudoephedrine is a demanding model compound for release control. Technologies demonstrated only with poorly soluble drugs may have limited transferability.

The commercial structure could include an upfront payment, development milestones, manufacturing royalties, or field-of-use restrictions covering decongestants and OTC respiratory products.

How strong is the Sudafed Sinus Congestion 24 Hour patent estate?

The product’s brand and distribution position are stronger than its likely molecule-level exclusivity position. Pseudoephedrine is an established OTC active, and the principal competitive moat is operational.

Estate component	Expected strength
Pseudoephedrine composition-of-matter rights	Minimal or expired
OTC regulatory status	Strong category access but not product exclusivity
24-hour formulation know-how	Potentially valuable and difficult to replicate exactly
Formulation patents	Moderate if technically narrow and supported by data
Manufacturing know-how	Potentially strong as a trade secret
Trademark	Strong against confusingly similar branding
Retail compliance infrastructure	Meaningful practical barrier
Biosimilar protection	Not applicable

The most defensible proprietary assets are likely process parameters, excipient grades, coating conditions, dissolution-control methods, and stability data. These assets may be more valuable in manufacturing and licensing negotiations than in patent litigation.

What revenue exposure exists from generic substitution?

Revenue exposure is likely concentrated in the branded premium and retail placement rather than in loss of molecule exclusivity. Generic substitution can pressure:

• Unit price.
• Shelf space.
• Pharmacy recommendation rates.
• Retailer margins.
• Promotional spending.
• Inventory commitments.
• Brand loyalty among price-sensitive consumers.

The strongest defense is a differentiated product proposition supported by measurable attributes such as smaller tablet size, improved swallowability, tamper resistance, better stability, or a cleaner inactive-ingredient profile.

A product that offers only the same 240 mg pseudoephedrine dose and the same 24-hour claim has limited protection from price competition.

What FDA regulatory issues affect reformulation?

A reformulation must preserve compliance with the applicable OTC monograph conditions and labeling requirements. Changes to excipient identity, level, manufacturing process, dosage form, or release profile may affect the regulatory basis for marketing.

Key regulatory workstreams include:

• Confirming the active ingredient and dosage conditions under the applicable OTC framework.
• Establishing release specifications for an extended-release product.
• Demonstrating stability under relevant storage conditions.
• Verifying content uniformity and assay.
• Assessing alcohol-induced dose dumping where relevant.
• Confirming compatibility with packaging.
• Reviewing warnings and directions for any dosage-form change.
• Evaluating the impact of tamper-resistant claims on labeling substantiation.

A commercially attractive excipient change can fail if it changes onset, total exposure, release duration, or consumer handling characteristics.

What is the best excipient strategy for a next-generation product?

The highest-value strategy is a robust hydrophilic matrix with a lower tablet mass, improved mechanical strength, and packaging optimized for moisture protection. The formulation should be designed around a broad manufacturing window rather than a single laboratory dissolution result.

A development program should prioritize:

1. Polymer grade and concentration screening.
2. Compression-force sensitivity.
3. Dissolution across pH conditions.
4. Mechanical abuse testing.
5. Stability under high-humidity conditions.
6. Tablet-size reduction.
7. Packaging-barrier comparison.
8. Scale-up reproducibility.
9. Consumer swallowability.
10. Comparative release testing against the market benchmark.

A second commercial pathway is an abuse-deterrent or tamper-resistant version. That strategy has greater differentiation potential but also higher development, substantiation, and regulatory costs.

Key Takeaways

• Sudafed Sinus Congestion 24 Hour contains pseudoephedrine hydrochloride 240 mg in an extended-release tablet.
• The main formulation challenge is controlling release from a highly water-soluble active for approximately 24 hours.
• The strongest excipient opportunities involve hydrophilic matrix optimization, tablet-size reduction, abuse deterrence, stability, and manufacturing efficiency.
• Conventional Orange Book and Paragraph IV analysis is less relevant because the product is positioned within the OTC monograph framework.
• Generic and private-label competition is structurally significant.
• The product’s practical moat is based on brand, retail access, compliance infrastructure, formulation know-how, and manufacturing capability.
• Formulation patents can add protection, but broad claims covering standard polymers and pseudoephedrine may be vulnerable.
• Biosimilar risk is not applicable because pseudoephedrine is a small-molecule active, not a biologic.
• The most commercially attractive next-generation product would combine a smaller tablet, robust 24-hour release, improved moisture stability, and defensible tamper-resistance characteristics.

FAQs

Can a new excipient create patent protection for pseudoephedrine 24-hour tablets?

Yes. Patentability may arise from a novel excipient combination, release profile, tablet architecture, manufacturing process, or abuse-deterrence performance. The claim must distinguish over known extended-release pseudoephedrine formulations.

Is hypromellose suitable for a 24-hour pseudoephedrine formulation?

Yes. Hypromellose is a widely used extended-release matrix polymer. Its suitability depends on viscosity grade, concentration, particle properties, compression conditions, and the resulting dissolution profile.

Can pseudoephedrine be reformulated as an abuse-deterrent product?

Yes. A formulation can be designed to resist crushing, extraction, or rapid release. Commercial claims require objective testing and careful regulatory review.

Would a pseudoephedrine liquid have the same commercial opportunity?

A liquid could improve administration for selected users, but achieving true 24-hour release, dose security, stability, and diversion resistance would be more difficult than with a matrix tablet or multiparticulate system.

Does a private-label product need to use the same Sudafed excipients?

No. A competing OTC product can use a different inactive-ingredient system if it satisfies applicable FDA requirements, supports the labeled dosage form and release characteristics, and complies with pseudoephedrine sales controls.

References

1. U.S. Food and Drug Administration. (n.d.). Sudafed Sinus Congestion 24 Hour product labeling. DailyMed.

2. U.S. Drug Enforcement Administration. (n.d.). Combat methamphetamine epidemic act requirements for retail sales of pseudoephedrine. U.S. Department of Justice.

3. U.S. Food and Drug Administration. (2023). Over-the-counter monograph drug products. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2023). FDA proposes removing oral phenylephrine from OTC monograph as nasal decongestant. U.S. Department of Health and Human Services.